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Background: Oncogenic human papillomavirus (HPV) has been hypothesised as a risk factor for oesophageal squamous cell
carcinoma (OSCC), but aetiological research has been limited by the varying methodology used for establishing HPV prevalence.
The aims of this systematic review and meta-analysis were to estimate the prevalence of HPV DNA detected in OSCC tumours and
the influence of study characteristics.
Methods: Study-level estimates of overall and type-specific HPV prevalence were meta-analysed to obtain random-effects
summary estimates.
Results: This analysis included 124 studies with a total of 13 832 OSCC cases. The average HPV prevalence (95% confidence interval)
among OSCC cases was 0.277 (0.234, 0.320) by polymerase chain reaction; 0.243 (0.159, 0.326) by in situ hybridisation; 0.304 (0.185,
0.423) by immunohistochemistry; 0.322 (0.154, 0.490) by L1 serology; and 0.176 (0.061, 0.292) by Southern/slot/dot blot. The highest
HPV prevalence was found in Africa and Asia, notably among Chinese studies from provinces with high OSCC incidence rates.
Conclusions: Future research should focus on quantifying HPV in OSCC cases using strict quality control measures, as well as
determining the association between HPV and OSCC incidence by conducting large, population-based case–control studies.
Such studies will provide a richer understanding of the role of HPV in OSCC aetiology.
Oesophageal cancer is the eighth most common cancer worldwide,
with an estimated 481 000 annual incident cases, and is the sixth
most common cause of cancer mortality, with an estimated 406 000
annual deaths (Ferlay et al, 2010). Incidence rates of oesophageal
cancer vary greatly by geographic region (Corley and Buffler, 2001;
Ferlay et al, 2010), with markedly high rates in the ‘Asian
Oesophageal Cancer Belt’, which extends from northern Iran, east
to China and north into Russia (Glenn, 2001; Kamangar et al,
2007; Wei et al, 2011). Reasons for the geographic variability are
not well understood (Hongo et al, 2009).
Squamous cell carcinoma is the most common form of
oesophageal cancer (Corley and Buffler, 2001). Epidemiological
studies conducted in the Western countries, Asia, and Africa have
concluded that tobacco and alcohol consumption are the main
known risk factors for OSCC (IARC, 1986; IARC, 1988; Munoz
and Castellsague, 1994), accounting for approximately 90% of
OSCC in men and 29% in women (Castellsague et al, 1999). Yet, it
has been suggested that alcohol and tobacco consumption are not
the major risk factors for OSCC in one of the highest risk areas of
northern China (Linxian County) (Yu et al, 1993). Additional
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established risk factors include poverty and nutritional deficiencies
(Hongo et al, 2009; Mao et al, 2011).
Infection with oncogenic HPV as a contributor to OSCC was
hypothesised over three decades ago (Syrjanen, 1982). However,
the International Agency for Cancer Research (IARC) has
concluded that there is inadequate evidence in humans for HPV
carcinogenicity in association with OSCC (IARC, 2012).
The aims of this systematic review and meta-analysis were to
estimate the prevalence of HPV detected in OSCC cases and the
influence of type of HPV detection methods and other study
characteristics on this measure.
MATERIALS AND METHODS
Search strategy and inclusion criteria. A systematic literature
search was conducted using MEDLINE (via PubMed) and Excerpta
Medica database (EMBASE) through 12 July 2013, with no
specified start date or language restrictions. This systematic review
was conducted in accordance with PRISMA guidelines (Moher
et al, 2009).
Broad search terms included: HPV, oesophagus, and cancer (e.g.,
neoplasm, carcinoma, tumour) (specific search terms available upon
request). Eligible studies included peer-reviewed publications with
HPV prevalence data from a minimum of 20 adult human cases of
primary, invasive, and oesophageal squamous cell carcinoma
(OSCC). Review articles and editorials were included if they
contained original data. Abstracts were excluded. Primary and
secondary references were searched to identify additional studies. A
medical reference librarian verified the search strategy, and
independently repeated the search. If multiple publications presented
data from the same population, only the publication with the largest
sample size was included. Articles written in languages other than
English were translated and reviewed. Because articles were excluded
based on multiple criteria, we assigned a primary exclusion criterion
based on the following rank-order: study not conducted in humans
(i.e., in vitro or animal study), not oesophageal cancer, histology
other than squamous cell carcinoma, not primary tumour, not
invasive cancer (i.e., in situ only), study population included only
children (i.e., o18 years old), letter to the editor or review (without
original data), case report, abstract, histology unidentified, o20
cases, and no quantification of HPV.
Data extraction. For studies meeting our inclusion criteria, the
following data were extracted: first author, publication year, study
location, dates of sample collection, sample size, specimen type,
HPV detection method, and overall and type-specific prevalence of
HPV. Continent, country, and region were recorded. For studies
with samples from multiple countries, data were extracted
separately by country when possible.
Studies were categorised into five geographical areas: Africa,
Asia, Europe and Australia, North America, or South and Central
America. In addition, we analysed separately the studies performed
in Iran and the high-OSCC-incidence province-level divisions of
China (i.e., provinces with higher than the overall crude incidence
of oesophageal cancer for China of 22.1/100 000) (Chen et al,
2013). These included Fujian, Gansu, Hebei, Henan, Jiangsu,
Shandong, Shanxi, and Sichuan provinces, as well as Xinjiang
Uyghar Autonomous Region.
Specimen type was classified as paraffin-embedded fixed
biopsies, fresh or frozen biopsies, or blood samples. HPV detection
method was classified as polymerase chain reaction (PCR), in situ
hybridisation (ISH), immunohistochemistry, serology, and South-
ern blot (including dot and slot blot). For studies that used
multiple HPV detection methods, overall and type-specific
prevalence of HPV were extracted independently. For studies that
utilised PCR, information on specific HPV primers used was also
extracted. For studies that reported use of multiple PCR primers,
only the three most sensitive primers were recorded. The following
rank order of sensitivity (from most to least sensitive), based on a
meta-analysis of invasive cervical cancer, was assumed: SPF10,
GP5þ /6þ , L1C1/2, MY09/11, PU1M/2R, GP5/6, L1, E6, E7,
HPV-16 specific, and HPV-18 specific (Clifford et al, 2003). HPV-
type-specific estimates were only recorded if the authors reported
which HPV types were tested. For studies that utilised serology,
data on HPV prevalence were extracted separately by serological
marker (i.e., L1 vs E6/E7).
Data extraction was performed for each article by two of five
independent reviewers (AMB, ABW, CC, JLP, XS) using a
standardized data extraction form, and discrepancies were resolved
by consensus. Study authors were contacted to obtain specific
needed information. This occurred when the reviewers were unable
to determine 1) HPV prevalence by detection method or 2) HPV
prevalence by HPV subtype.
Statistical analysis. For each study, overall HPV prevalence
estimates were calculated as the percentage of OSCC cases who
tested positive for any HPV type. In some studies, the total number
of available OSCC cases differed from the number of OSCC cases
actually tested for HPV (e.g., cases were not tested if they were
beta-globin-negative). Additionally, if one HPV detection method
was utilised as a screening method for another, we did not include
the results of the secondary screening method in our analyses.
Information on all HPV-based studies is presented in
Supplementary Table 1. The number of OSCC cases tested was
used as the denominator. For studies reporting type-specific HPV
prevalence, estimates were calculated as percentages of OSCC cases
(same denominator as for overall prevalence) that tested positive
for a single type of HPV. Infections for multiple types of HPV were
separated into types; thus, type-specific prevalence represents types
for tumours with either single or multiple infections. Data on
overall and type-specific HPV prevalence are presented for each
study in the appendices by HPV detection method. We calculated
the variance of each prevalence estimate as pq/n, where p is the
prevalence, q is 1 p, and n is the number of OSCC cases
(Barendregt et al, 2013).
For studies reporting HPV prevalence equal to zero we used an
empirical continuity correction method described by Sweeting et al
(2004) to smooth the zero values. Specifically, we estimated the
pooled prevalence, by detection method, for studies with non-zero
prevalence estimates. These estimates divided by 100 were then
used as the number of HPV-positive OSCC cases, and 1 minus the
value added to the HPV-positive OSCC cases was added to the
number of HPV-negative OSCC cases. A similar approach was
used to smooth HPV type-specific estimates in studies that
explicitly reported zero OSCC cases that were positive for a
particular HPV type (e.g., 0 OSCC cases who were HPV-16
positive). If studies did not explicitly report type-specific HPV
prevalence, this information was considered missing and not
smoothed.
Two studies (Ma et al, 2000; Sitas et al, 2012) provided only
type-specific HPV prevalence estimates, and overall HPV pre-
valence estimates could not be determined (i.e., unable to reconcile
single vs multiple type infections). In such instances, the overall
HPV prevalence was considered to be missing and was not
smoothed but these studies were included in the type-specific
analyses.
For the analyses, we used three models: (1) crude model, (2)
univariable model, and (3) multivariable model. The crude model
was run by HPV detection type for overall prevalence of HPV
(Supplementary Table 2). The univariable model was used to
explore the heterogeneity of overall random-effects estimates
(Table 2). Both overall (Table 2) and prevalence estimates stratified
by HPV detection type (Supplementary Table 2) were considered
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from models that included HPV prevalence and disjoint indicator
variables for a single study characteristic that included: geographic
location, publication date, DNA source, and primer set (for PCR
only). For example, running an overall HPV prevalence model for
HPV detection type would include HPV prevalence and a disjoint
indicator variable for the HPV detection types (i.e., PCR, ISH,
immunohistochemistry, serology, and Southern blot) but no other
covariates. Median values of HPV prevalence were also calculated
(Supplementary Table 2). The multivariable model of HPV
prevalence was adjusted for all study characteristics (i.e., HPV
detection method, continent, publication date, and study size)
(Table 2). For all models, study-level estimates of overall and type-
specific HPV prevalence were meta-analysed using the metareg
command in STATA to obtain random-effects summary estimates
(DerSimonian and Laird, 1986; Thompson and Sharp, 1999).
In the crude models, we also estimated the among-population
variance (t2). Tau-squared is the variance of the presumptively
normal distribution of true values among populations in which
each population has its own true value (i.e., its own true HPV
prevalence). We utilised t2 to calculate a 95% population effects
interval (PEI) within which 95% of the populations’ true values are
estimated to lie (i.e., mean prevalence±1.96*t) (Mosteller and
Colditz, 1996; Ludema et al, 2011). To calculate the PEI, we used a
logit transformation (Barendregt et al, 2013).
Two sensitivity analyses were performed to assess the robustness
of the results. First, the analysis was performed excluding the PCR
studies with beta-globin-negative cases (i.e., the studies where the
total number of available OSCC cases differed from the number of
OSCC cases actually tested for HPV) to assess the overall influence
of these data on the estimates. Second, summary estimates of
overall HPV prevalence were calculated for the serology studies,
stratified by L1 and E6/E7 antigen status.
Meta-analyses were performed using STATA version 12 for
Windows (StataCorp LP, College Station, TX, USA). Ancillary
analyses were performed using SAS version 9.2 (SAS Institute, Inc.,
Cary, NC, USA).
RESULTS
Systematic review and study characteristics. Our systematic
search of PubMed and EMBASE resulted in 724 unique papers.
Of these, 124 (17.1%) studies were eligible and included in this
systematic review and meta-analysis. Of the remaining 600
publications, 585 (97.5%) were excluded based on various
exclusion criteria, 14 (2.3%) were duplicate study populations,
and 1 (0.2%) was ineligible after contacting the author. The
primary reasons for exclusion included the following: the outcome
studied not being oesophageal cancer (n¼ 185 publications) and
the paper being a review article or letter to the editor without
original data (n¼ 137 publications) (Figure 1).
Individual characteristics of the included 124 studies are
summarised in Supplementary Table 1. Study sample sizes ranged
from 20 to 1561 OSCC cases (median¼ 60). Summing across
studies, a total of 14 047 OSCC cases were identified. However, as
215 case samples did not have sufficient DNA for analysis, a total
of 13 832 OSCC cases were included in the analysis. As reported in
Table 1, the majority of studies were conducted in Asian countries
(n¼ 77, 62.1%), with the remaining studies spanning five
other continents as follows: 20 (16.1%) studies in Europe, 9
(7.3%) studies in Africa, 8 (6.5%) studies in North America,
4 (3.2%) studies in South America, 1 (0.8%) study in Australia,
and 5 (4.0%) studies included populations from more than one
continent. The majority (70.9%) of the Chinese studies were from
the high-OSCC-incidence provinces of China. For multi-country
studies, information was extracted separately by country for five
multi-continent studies (Togawa et al, 1994; Suzuk et al, 1996;
Wang et al, 2010; Castillo et al, 2011; Sitas et al, 2012) and for five
single-continent studies (Mori et al, 1989; Turner et al, 1997;
Kawaguchi et al, 2000; Castillo et al, 2006; Goto et al, 2011).
The majority of studies (n¼ 90, 72.6%) used only one
laboratory detection method to detect HPV, whereas 29
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Figure 1. Flow diagram of inclusion and exclusion of identified studies for the meta-analysis of overall prevalence of human papillomavirus (HPV)
among oesophageal squamous cell carcinoma (OSCC) cases. Although many articles were excluded based on multiple criteria, we assigned
primary exclusion criteria according to the following rank order: study not conducted in humans (i.e., in vitro or animal study), not oesophageal
cancer, not squamous cell carcinoma (histology known), not primary tumour, not invasive (i.e., in situ only), study population children only
(i.e., o18 years old), letter to the editor or review (without original data), case report, abstract, histology unidentified, o20 cases, and no
quantification of HPV.
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used three detection methods. The total number of estimates was
174 summing the across-study populations and detection
methods. The majority of the estimates (n¼ 109, 62.6%) were
based on PCR methods (Table 2).
Meta-analysis of HPV prevalence in OSCC cases. The pooled
prevalence estimates for studies with non-zero prevalence estimates,
stratified by detection method, were 0.325 by PCR; 0.312 by ISH;
0.359 by immunohistochemistry; 0.321 by L1 serology; and 0.201
Table 1. Selected characteristics of 124 studies included in the meta-analysis of overall prevalence of human papillomavirus (HPV) among oesophageal
squamous cell carcinoma (OSCC) cases
Continent Studies, N
OSCC
Cases, Na Countries represented
Africa 9 1235 Egypt, Kenya, South Africa
Asia 77 9861 Chinab, India, Iran, Japan, Pakistan, South Korea, Taiwan, Turkey
Australia 1 433 Australia
Europe 20 1275 Belgium, Czech Republic, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, Norway, Poland,
Romania, Russia, Slovenia, Sweden, United Kingdom
North America 8 280 Canada, Mexico, United States
South America 4 748 Brazil, Chile, Colombia
Multi-continent 5 —
Total 124 13 832
aFor the five multi-continent studies, data extraction was performed separately by country (Togawa et al, 1994; Suzuk et al, 1996; Wang et al, 2010; Castillo et al, 2011; Sitas et al, 2012).
Therefore, the OSCC cases from these studies were reported by continent.
bOf 55 studies performed in China, 39 (70.9%) were performed in high OSCC incidence provinces of China.













Intercepte 0.403 (0.337, 0.470)
HPV detection method Prevalence (95% CI) Prevalence Difference (95% CI)
PCR 95 109 9257 0.277 (0.234, 0.320) REF
In situ hybridisation 25 28 2631 0.243 (0.159, 0.326) 0.034 ( 0.126, 0.059)
Immunohistochemistry 7 7 773 0.304 (0.185, 0.423) 0.067 ( 0.191, 0.058)
Serology 14 14 862 0.322 (0.154, 0.490) 0.112 ( 0.054, 0.277)
Southern blot 11 16 556 0.176 (0.061, 0.292) 0.067 ( 0.191, 0.058)
Continent
Asia 84 116 10 985 0.314 (0.274, 0.354) REF
Europe/Australia 22 27 1410 0.156 (0.073, 0.238) 0.180 ( 0.277, 0.084)
North America 8 11 350 0.166 (0.036, 0.296) 0.166 ( 0.304, 0.027)
South America 5 8 664 0.194 (0.042, 0.346) 0.169 ( 0.327, 0.011)
Africa 10 12 670 0.198 (0.075, 0.322) 0.113 ( 0.244, 0.018)
Publication date
2000 to present 83 105 10 621 0.310 (0.267, 0.352) REF
1990–1999 36 65 3322 0.204 (0.149, 0.259) 0.093 ( 0.168, 0.017)
Prior to 1990 3 4 136 0.103 ( 0.114, 0.321) 0.282 ( 0.536, 0.029)
Study size
p60 OSCC cases 65 98 3410 0.272 (0.226, 0.318) REF
460 OSCC cases 63 76 10 669 0.261 (0.211, 0.311) 0.092 ( 0.162, 0.023)
aTwo studies that did not report overall HPV were excluded (Ma et al, 2000; Sitas et al, 2012).
bCategories are exclusive for estimates but not for studies because some studies presented results for multiple detection methods.
cUnivariable meta-regression of a single study characteristic, where the HPV prevalence estimates are not controlled for other study characteristics. For example, the prevalence of
PCR is adjusted for other HPV detection types (i.e., in situ hybridisation, immunohistochemistry, serology and Southern blot) but no other study characteristics (i.e., continent, publication date,
or study size).
dMultivariable meta-regression, where the HPV prevalence estimates are controlled for all other study characteristics in the table.
eIntercept: Asian PCR studies conducted 2000 to present with p60 OSCC cases.
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by Southern and other blotting techniques. We utilised the
unrounded values of these prevalence estimates to smooth values
for studies with zero HPV-positive cases.
The overall random-effects summary estimates from the crude
model for HPV were similar across detection methods. The average
prevalence of HPV (95% confidence interval (CI)) was 0.278 (95%
CI: 0.233, 0.322) by PCR; 0.242 (95% CI: 0.157, 0.328) by ISH;
0.305 (95% CI: 0.160, 0.450) by immunohistochemistry; 0.321
(95% CI: 0.156, 0.486) by L1 serology; and 0.166 (95% CI: 0.097,
0.234) by Southern blot (Supplementary Table 2). Utilising the
logit transformation, the average prevalence of HPV (95%
population effects interval (PEI)) was 0.292 (95% PEI: 0.039,
0.809) by PCR; 0.280 (95% PEI: 0.045, 0.763) by ISH; 0.329
(95% PEI: 0.050, 0.821) by immunohistochemistry; 0.302 (95%
PEI: 0.075, 0.698) by L1 serology; and 0.213 (95% PEI: 0.084,
0.442) by Southern blot (data not shown in tables). In general, the
median per cent positive estimates were similar to the summary
medians. The median prevalence of overall HPV positivity was
0.211 by PCR; 0.221 by ISH; 0.232 by immunohistochemistry;
0.275 by L1 serology; and 0.180 by Southern blot (Supplementary
Table 2).
In the univariable model, the mean HPV prevalence was 0.277
(95% CI: 0.234, 0.320) for PCR, 0.314 (95% CI: 0.274, 0.354) for
Asia, 0.310 (95% CI: 0.267, 0.352) for publications after 1999, and
0.272 (95% CI: 0.226, 0.318) for studies with p60 cases. In the
multivariable meta-regression analysis, the mean HPV prevalence
for the intercept (Asian PCR studies conducted after 1999 with
p60 cases) was 0.403 (95% CI: 0.337, 0.470). By detection method,
estimates for L1 serology were the most different from PCR, with a
prevalence difference of 0.112 higher than the intercept. Among
continents, Europe/Australia was the most different from Asia,
with a prevalence difference of  0.180. Studies conducted prior to
1990 were the most different from studies conducted from 2000 to
present, with a prevalence difference of  0.282. Finally, studies
with 460 cases had a prevalence difference of  0.092 compared
with studies with p60 cases (Table 2).
The range for HPV prevalence was 0–84.1% for PCR; 0–72.3% for
ISH; 0–73.3% for immunohistochemistry; 3.2–58.5% for serology;
and 0–45.0% for Southern/slot/dot blot (Supplementary Table 1).
The prevalence of high-risk types of HPV, namely HPV-16 and -18,
was fairly similar across PCR, ISH, and Southern blot, but differed
slightly for serology and immunohistochemistry (Supplementary
Table 2). HPV-16 prevalence was 0.185 (95% CI: 0.142, 0.228) for
PCR; 0.255 (95% CI: 0.114, 0.397) for ISH; 0.359 (95% CI:  0.101,
0.819) for immunohistochemistry; 0.173 (95% CI: 0.087, 0.259) for
L1 serology; and 0.187 (95% CI: 0.116, 0.259) for Southern blot.
Median prevalence estimates for HPV-16 were 0.132 for PCR; 0.190
for ISH; 0.430 for immunohistochemistry; 0.084 for L1 serology; and
0.198 for Southern blot.
Results stratified by detection method for HPV prevalence
according to continent, publication year, DNA source, and primer
set (for PCR only) are provided in Supplementary Table 2. As with
the meta-regression, striking differences were noted for study
location across HPV detection methods. Trends across publication
year, tissue source, and primer set were noted but were not as
consistent across detection methods (Supplementary Table 2).
We also examined within-study comparison for studies that had
both PCR and ISH (n¼ 11), PCR and Southern blot (n¼ 9), PCR
and immunohistochemistry (n¼ 3), ISH and immunohistochem-
istry (n¼ 4), ISH and Southern blot (n¼ 3), and HPV 16 and 18
(n¼ 62). The results from these analyses were similar to our overall
results. For example, the within-study meta-analysis for ISH
compared with PCR resulted in a prevalence difference of  0.038
(95% CI:  0.024, 0.164), based on a mean prevalence of 0.202
(95% CI: 0.059, 0.345) for PCR (data not shown in tables).
In our sensitivity analyses, results were similar when excluding
the PCR studies with beta-globin-negative cases. When the PCR
analysis is restricted to only studies with all beta-globin-positive
cases, the overall HPV prevalence is 0.288 (95% CI: 0.238, 0.338).
However, results were dissimilar for serology studies when
stratified by L1 or E6/E7 antigen status. For example, the overall
HPV prevalence for E6/E7 antigen status studies was 0.100 (95%
CI:  0.777, 0.978). These results were based on only two studies
that utilised E6/E7 antigen status (Dai et al, 2007; Guo et al, 2012).
Therefore, only L1 serology results are presented in the tables.
DISCUSSION
This systematic review and meta-analysis of the literature on HPV
prevalence combined data on 13 832 OSCC cases from 124 studies.
In our study, we utilised multivariable meta-regression methods to
analyse HPV prevalence in OSCC tumours. We summarised the
influence of several important factors on HPV prevalence in OSCC
cases, including HPV detection method, geographic location,
publication date, and study size.
The prevalence of overall HPV varied widely across detection
methods, ranging from 17.6% for Southern blot to 32.2% for L1
serology. Our assessment of heterogeneity suggested meaningful
variation in HPV prevalence across HPV detection methods. The
estimates of overall HPV prevalence from our meta-analysis are
consistent with a recent meta-analysis by Syrjanen, which
reported an overall summary HPV prevalence of 29.0% (95% CI:
25.1–33.1%), after combining data on histological biopsies, dot blot
hybridisation, filter ISH, hybrid capture 2 assay, ISH, PCR, and
Southern blot hybridisation (Syrjanen, 2013). In contrast, we have
only presented stratum-specific estimates by detection method in
order to elucidate the heterogeneity in HPV prevalence estimates.
Each detection method has strengths and limitations with regard to
measurement of possible infection at different time points,
technical requirements, and test characteristics. For instance,
PCR, Southern blot, and ISH have high specificity, ISH has low
sensitivity, and PCR has a high rate of false positives (Kimple et al,
2012).
Further, it is uninformative to estimate an overall (i.e.,
worldwide) HPV prevalence, as it is a function of the number of
HPV types that are tested and a host of other methodologic
determinants as well as highly variable characteristics of person,
place, and time. Testing for additional HPV types could partially
account for the increasing prevalence across time. However, this
seems unlikely as HPV-16 is the predominant type detected and is
nearly always tested for as a high-risk HPV type.
The observed differences in HPV prevalence by geographic
location warrant further attention. Most notably, our study
uniquely reports estimates for overall HPV prevalence in Chinese
regions characterised by the high incidence of OSCC. Our
estimates of HPV prevalence in these Chinese regions, ranging
from 26.4% (95% CI: 10.8%, 42.0%) for Southern blot to 41.6%
(95% CI: 33.1%, 50.2%) for PCR, are substantially higher than any
continent-specific estimates, including other regions of Asia.
Interestingly, all of our detection method-specific estimates for
high-risk provinces of China are lower than the estimate of 41.8%
(95% CI: 34.3%, 49.7%) reported by Syrjanen (2013) for Chinese
studies, which includes both high- and low-risk Chinese regions.
This is possible due to the inclusion of additional detection types
not included in our analysis (e.g., histological biopsies, hybrid
capture 2 assay). In a continent-specific analysis stratified by the
HPV detection method, we found that HPV prevalence was highest
in Asia and Africa and similar across all other continents. These
results are consistent with (1) the estimates reported by Syrjanen
that show high prevalence in China and South Africa (Syrjanen,
2013) and (2) a systematic review by Liyanage et al (2013)
that reported higher levels of HPV detection in regions with high
OSCC risk.
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Although the geographic differences in oral HPV prevalence are
notable (Kreimer et al, 2010), HPV cannot be expected to fully
account for the geographical variation seen in OSCC incidence
(Ferlay et al, 2013). Even when an infectious agent participates in
the aetiology of every case of a disease (e.g., tubercle bacillus and
tuberculosis, Plasmodium protozoa and malaria, or HIV and
AIDS), aetiologic co-factors help determine the disease’s geo-
graphic variation.
Further, these findings need to be cautiously interpreted, as they
do not account for the background prevalence of HPV. Future
studies need to account for the background prevalence of HPV,
which varies widely by region. A recent meta-analysis examined
the prevalence of oral HPV, ranging from approximately 2.6% in
Canada to 18.9% in Brazil (Kreimer et al, 2010). Additionally, this
review cannot account for other established risk factors, including
tobacco, alcohol, poverty, and nutritional deficiencies (IARC, 1986;
IARC, 1988; Munoz and Castellsague, 1994; Hongo et al, 2009;
Mao et al, 2011).
HPV-16 was the predominant type of HPV assayed and
identified across detection methods, with the exception of L1
serology. In stratified analyses, HPV-16 prevalence ranged from
17.3% for L1 serology to 35.9% for immunohistochemistry. HPV-
18 was the predominate type of HPV identified for L1 serology,
with a prevalence of 26.0%. HPV-18 prevalence ranged from 0%
for immunohistochemistry to 26.0% for L1 serology. Our results
for PCR were consistent with a recent meta-analysis by Yong et al
(2013), which reported a HPV-16 prevalence of 11.7% (95% CI:
7.7%, 16.2%) and a HPV-18 prevalence of 1.8% (95% CI: 0.9%,
3.0%) in OSCC tumours detected with PCR alone. Unlike previous
studies, our analysis also summarises the differences in HPV type-
specific prevalence across multiple detection methods.
Characterising the prevalence of HPV in OSCC cases is an
important preliminary step to assessing the association between
HPV and OSCC. The prevalence of HPV among OSCC cases in
this meta-analysis is lower than the prevalence of HPV previously
observed for other cancers with more established epidemiologic
evidence for HPV involvement, such as cervical, anal, orophar-
yngeal, or tonsillar (IARC, 2012). Nonetheless, the HPV prevalence
in OSCC cases is high enough, and correlated strongly enough with
OSCC incidence ecologically, suggesting that an aetiologic
connection might be present between the virus and the cancer.
By way of analogy, we note that the prevalence of cigarette
smoking is lower in bladder cancer cases than in cases of lung
cancer. A causal connection between smoking and bladder cancer
was established nonetheless. The requisite research took longer,
largely because smoking’s association with bladder cancer, though
causal, was weaker than its association with lung cancer.
An association between HPV and OSCC is biologically plausible
on the basis of (1) the close proximity and histologic similarities
between oesophageal and oral squamous epithelium – suggesting
that the oesophagus could be exposed to HPV in a similar fashion
as the oral cavity and oropharynx (Gillison and Shah, 2003); (2) the
detection of HPV DNA in both benign oesophageal squamous cell
papillomas and malignant OSCC tumour samples (Syrjanen, 2002);
(3) in vivo studies in cattle, showing that bovine papillomavirus
leads to the development of papillomas, then to squamous cell
carcinoma (Borzacchiello and Roperto, 2008); and (4) in vitro
experiments of human oesophageal epithelial cells where HPV-18
was shown to be an initiating factor in cancer transformation
(Shen et al, 2000). However, counterarguments have been
suggested, including the lack of association between OSCC and
immunosuppression or previous HPV-associated disease (Gillison
and Shah, 2003) and wide variability in case-series report of HPV
positivity in OSCC cases (Syrjanen, 2002) – ranging worldwide
from over 70% positivity (Liu et al, 2000; Cao et al, 2005; Zhu et al,
2005; Yang et al, 2008; Ding et al, 2009; Qu et al, 2012) to 0% (Hale
et al, 1989; Loke et al, 1990; Benamouzig et al, 1995; Smits et al,
1995; Saegusa, 1997; Morgan et al, 1997; Kamath et al, 2000;
Talamini et al, 2000; Awerkiew et al, 2003; White et al, 2005; Koh
et al, 2008; Bellizzi et al, 2009; Song et al, 2009; Patel et al, 2011;
Noori et al, 2012; Haeri et al, 2013). Even within countries, the
prevalence of HPV varies widely. For example, in one Chinese
study, HPV positivity in OSCC tumours has been reported to
range from 2.0% in Linxian province to 22.2% in Shantou province
(Si et al, 2003). This variation is unlikely due to differences in the
study methodology. The large variation in HPV DNA prevalence
estimates in OSCC tumours across geographical sites has not been
fully explained, but it could possibly be due to small sample sizes,
differing HPV detection methods and PCR primers, cut points
utilised for HPV positivity, variability between laboratories, and
contamination of samples (Hubbard, 2003; Koshiol et al, 2010).
Contamination of samples is of paramount concern, as studies
have reported that dehydrated HPV maintains 100% infectivity for
as long as a day (Roden et al, 1997). Additional studies have found
HPV DNA on fomites and various medical surfaces (Ferenczy et al,
1989; Strauss et al, 2002). This is problematic because HPV DNA is
resistant to cleaning detergents (Strauss et al, 2003), which leads to
concerns that fomites could be responsible for contaminating
samples (Roden et al, 1997). Although we attempted to evaluate
quality control measures, this was difficult as many studies do not
report on these issues, and we were concerned about biasing our
results by including only studies that report on quality control
measures. Future studies should strive to carefully avoid contam-
ination and to report quality control measures.
Limitations of the current meta-analysis should be considered.
Bias could arise from the study estimates because the accuracy of
these estimates depends on the detection method utilised and the
types of HPV assessed. That is, some studies utilised broad
primers or multiple probes to detect multiple types of HPV,
whereas other studies only detected a specific HPV type
(e.g., HPV-16). Additionally, there is potential publication bias.
This potential is seen in the multivariable meta-regression,
which suggests that smaller studies may have higher reported
prevalence. Finally, we used a continent-level variable to
categorise studies, in addition to high-risk China and Iran. This
classification may have masked important variability between
studies on the same continent.
The studies included in this meta-analysis are heterogeneous.
We directly examined heterogeneity by describing the prevalence
of HPV in OSCC cases by HPV type, continent, publication date,
DNA source, and primer set. Of course, we were not fully able to
explain the heterogeneity. Prevalence estimates remained
heterogeneous even in stratified results (e.g., PCR studies
conducted in Asia). This is to be expected, as a full explanation
of heterogeneity would require knowledge of every determinant of
HPV prevalence in OSCC cases, as well as every determinant of
HPV measurement validity and reliability, and a sufficient number
of studies to explore possible combinations of all such variables.
Nonetheless, we identified several variables that account for
substantial portions of the heterogeneity.
Strengths of the current meta-analysis include large overall
sample size, use of multivariable meta-regression to assess study
characteristics, examination of type-specific HPV prevalence,
inclusion of studies published in all languages, and exclusion of
case reports or studies with small sample size. The use of
multivariable meta-regression allowed us to determine study
characteristics that influence heterogeneity of HPV prevalence
estimates. By examining type-specific HPV prevalence, we were
able to determine what is the predominate type of HPV detected in
OSCC cases. However, we are still dependent on the HPV types
that are included in the primer sets, which are largely optimised for
the detection of HPV genital types. By including studies of all
languages, we avoided selection bias due to publication language.
Finally, by excluding case reports and studies with o20 cases, we
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attempted to exclude studies that were a convenience sample or not
representative of all OSCC cases.
Although a high proportion of OSCC cases with prevalent HPV
does not determine aetiologic significance, the data presented in
this paper strongly indicate that such a hypothesis warrants further
investigation. Similar to that which has been done for head and
neck cancer (Agrawal et al, 2011), advances in aetiologic under-
standing of the role of HPV in OSCC tumour development will
come from exome sequencing, which will ideally be conducted in a
large number of tumours from differing geographic locals and
differing tumour sites.
In summary, our results suggest that HPV prevalence in OSCC
tumours is highest in Africa and Asia, especially in the regions of
China with a high incidence of OSCC, and that high-risk HPV-16
is the most commonly identified HPV type in OSCC tumours. Our
meta-analysis demonstrates that HPV detection method, con-
tinent, publication date, and study size contribute to the variability
among individual study findings. Utilising multivariable meta-
regression, this systematic review highlights study characteristics
that need to be considered when examining the association
between HPV infection and OSCC. Although this review is a
preliminary step in assessing the relationship between HPV and
OSCC, it may also be used to better tailor monitoring and public
health interventions (e.g., HPV vaccinations) if that relationship
becomes established as causal. Future research should focus on
quantifying HPV in OSCC cases using strict quality control
measures to avoid contamination, as well as determining the
association between HPV and OSCC incidence by conducting
large, population-based case–control studies. Such studies will
provide a richer understanding of the role of HPV in OSCC
aetiology.
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